Background
Since the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) showed an improved 5-year overall survival after neoadjuvant chemoradiotherapy (nCRT) plus surgery compared to surgery alone, trimodality treatment has become a standard of care for resectable esophageal cancer [
1‐
3]. The CROSS trial also showed that nearly a third of patients had a pathologically complete response (pCR) [
1]. Estimated 5-year survival in patients with pCR is between 70 and 80% [
4]. However, surgery likely has not contributed to this favorable outcome since this improved survival can be attributed to the introduction of neoadjuvant chemoradiotherapy [
1]. Active surveillance could therefore be considered as an alternative treatment option in patients with a clinically complete response (cCR) after nCRT. To assess whether patients achieve cCR, response evaluations are performed consisting of
18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scan, upper endoscopy with bite-on-bite biopsies, and endoscopic ultrasound with fine-needle aspiration (EUS-FNA) of suspicious lymph nodes. Only when locoregional regrowth of cancer is (cyto)histologically proven or is highly suspected in the absence of distant metastases, patients are offered surgical resection.
The benefit of active surveillance might be that patients will not need esophagectomy in case of persistent cCR after nCRT. Esophagectomy is associated with substantial morbidity and has a lasting impact on patients’ health-related quality of life [
5‐
7]. Also, patients who develop (early) distant metastases despite locoregional control of the disease are spared futile surgery. Hence, some 50% of patients still develop distant metastases despite radical surgery of which 75% of these within 2 years after esophagectomy. This underlines the current shortcomings of proper patient selection for curative treatment.
On the other hand, active surveillance has risks. Regrowth of tumor might remain undetected despite clinical response evaluations. This could lead to a non-resectable tumor or the development of metastases from residual tumor cells. Furthermore, delayed surgery might be associated with an increased postoperative morbidity [
8].
Active surveillance or watchful waiting is already being applied in patients with rectal cancer. According to the 2019 Dutch guideline on colorectal cancer, watchful waiting should be discussed as an alternative to surgery in patients with cCR after nCRT [
9]. However, implementation of watchful waiting instead of standard surgery after nCRT for rectal cancer is not supported by data from randomized trials, but based on data from observational studies including a multicenter registration study [
10]. In esophageal cancer, randomized trials are still needed to show the safety and efficacy of active surveillance. The Surgery As Needed for Oesophageal Cancer (SANO) trial was initiated late in 2017 [
11,
12]. The SANO trial was designed to test non-inferiority of active surveillance compared to standard esophagectomy after nCRT, and randomized hospitals to one of the two strategies in a cluster-randomized design. Inclusion of patients with cCR was finished mid-2021 and the primary endpoint (
i.e. overall survival after at least two years) will be available end 2023. In France as well, a study on active surveillance is performed (Esostrate trial) in patients with epidermoid carcinoma or adenocarcinoma of the esophagus [
13].
Several observations have been made during the SANO trial supporting the willingness of patients to opt for active surveillance. In the hospitals randomized to standard surgery, 25% of patients who obtained cCR refused an operation and requested active surveillance instead. In the hospitals randomized to active surveillance, less than 1% of patients switched to standard surgery. This is in line with a previous discrete choice study in which patients were willing to trade off 15% chance of being cured at 5 years after nCRT in order to circumvent surgery [
14]. Furthermore, a recent individual patient-data meta-analysis showed comparable overall survival between active surveillance and standard esophagectomy in patients with locally advanced esophageal cancer [
15]. The Dutch patient federation for cancer of the digestive tract is also closely involved and supports active surveillance.
Given these observations, active surveillance may be offered as an alternative to standard surgery after nCRT whilst patients are registered in a prospective study setting and the compliance to the active surveillance protocol is continuously monitored. The aim of the SANO-2 study is to monitor safety, adherence and effectiveness of active surveillance in patients that opt for active surveillance before the results of randomized studies become available.
Discussion
SANO-2 is a prospective observational extension study, investigating the safety, adherence and effectiveness of active surveillance in patients with resectable esophageal cancer or cancer of the EGJ.
Offering active surveillance to patients after nCRT as an alternative to standard surgery while awaiting safety and efficacy data from randomized phase-III trials can be debated. A meta-analysis of 7 cohort studies showed that overall survival between patients undergoing standard surgery or active surveillance after nCRT is comparable [
15]. However, this study has several possible confounders. The study included predominantly retrospective studies with a small sample size. Patients included in active surveillance were highly selected and possibly represent a group with a more favorable prognosis. In addition, the standard surgery group did not include patients who refused surgery or were unfit for surgery which, despite propensity score matching, results in substantial selection bias. Also, the rate and timing of distant metastases were not sufficiently reported for a reliable comparison between the groups, and diagnostic tests used in response evaluations differed between the studies.
The Dutch patient federation for cancer of the digestive tract states that active surveillance for esophageal cancer should be discussed with patients while awaiting SANO results, as there was equipoise for active surveillance in a randomized study design. Secondly, there have been no safety issues reported so far and patients should be given the opportunity to make a well-informed shared decision for active surveillance based on the currently available data. The potential risks associated with active surveillance are regrowth of tumor that may be detected beyond the resectability limit, development of distant metastases from residual disease and a possible increase in postoperative morbidity of delayed surgery. The meta-analysis reported that 39% of patients in the active surveillance group developed locoregional recurrence after a median follow-up of 50 months of whom seven patients (7.5%) had synchronous distant metastases. Importantly, a radical resection rate (R0) of 95% was reached in patients undergoing postponed esophagectomy [
15].
To ensure that tumor regrowth after nCRT will be detected at a curable stage, surveillance is performed. The majority of locoregional regrowths are expected to occur within 12 months after nCRT, and nearly all within 24 months after nCRT. For now, the SANO protocol stipulates that all patients will undergo response evaluations for 5 years. It may well be that the frequency and duration of clinical response evaluations could be tailored according to histological tumor type, since esophageal squamous cell carcinomas are more sensitive to nCRT than adenocarcinomas leading to a higher percentage of pCR. However, thus far it remains unknown if the chance for regrowth of cancer is also lower in patients with squamous cell cancer. It is also important to assess patient’s wishes regarding continuation of active surveillance and whether there is a disproportionate recurring fear for the outcome of the response evaluations, which will be measured using the Cancer Worry Scale [
24]. Also, indications for surgery may expand. For example, in patients with oligometastatic disease there may be room for curative treatment options including esophagectomy as part of an intense multimodality treatment [
26].
The present study protocol defines that surgical resection should also be offered to patients with suspected locoregional regrowth to minimize the risk that clinically suspicious lesions with indefinite histological proof advance to an incurable disease stage. It may be difficult for the pathologist to detect viable cancer cells in a biopsy specimen given the irradiated tumor with inflammatory and reactive changes. Clinical response evaluations are not infallible. Data from the preSANO trial showed false-negative results of endoscopy with bite-on-bite biopsies and EUS-FNA in 10% [
17]. Therefore, in case of suspicion of residual tumor or high-grade dysplasia, immediate surgery is advised. In patients with an esophagus stricture and a non-traversable tumor on upper endoscopy, accurate surveillance of the tumor bed is impossible and therefore patients are advised to undergo surgery. So far, approximately half of the patients with a non-traversable tumor on upper endoscopy have residual tumor in the resection specimen (preliminary data from the SANO trial and SANO-2 study). Data from the SANO trial and the present study will hopefully supply more information on these important considerations, and this will affect implementation of active surveillance in standard practice when non-inferiority is proven.
Making a well-informed decision between an ‘experimental treatment’ and ‘standard treatment’ is difficult for patients in clinical practice [
27]. Some patients feel choosing active surveillance as ‘giving up’ or may feel that the stress associated with frequent CREs may not outweigh the likelihood that surgery can be omitted. Decision counselling is a tool to elicit, explore and discuss patients’ preferences in such a way, that patients are enabled to reflect on all aspects of their preference. It is not the purpose of this consultation to make patients change their mind, but rather to ensure that they have had the opportunity to consider pre-established and well-balanced information on both treatments options and are challenged to thoroughly consider the consequences of each option for them personally. Decision counselling is included in the SANO-2 study to give insight into the patient’s information needs and allows us to develop decision aids. This provides an opportunity for clinicians to gain experience of how active surveillance can be discussed as alternative treatment option in clinical practice. Standardizing patient information on a national level will increase patients’ empowerment, enhance shared decision making and reduce interhospital variation.
The term ‘active surveillance’ reflects the use of response evaluations to detect regrowth of cancer. For rectal cancer or prostate cancer, definitions such as ‘wait and see’ or ‘watchful waiting’ are frequently used. The term ‘watchful waiting’ gives the impression that less intense monitoring of tumor regrowth is used. Similar to a recent consensus statement in prostate cancer by international experts, it will also be helpful to obtain unambiguous use of semantics in active surveillance for esophageal cancer [
28]. Watchful waiting with selective delayed intervention is already being used in several other cancers including rectal cancer and prostate cancer [
9,
29]. For rectal cancer, watchful waiting was applied in a few highly specialized centers within the framework of clinical trials. The application of watchful waiting is currently being expanded worldwide, whereby patients can be registered and monitored in an international database to ensure a certain level of quality control. A recent analysis of this registry showed no difference in 5-year survival and distant dissemination rate between patients undergoing watchful waiting or standard resection [
10]. In contrast to active surveillance in esophageal cancer, watchful waiting in rectal cancer patients is recommended as alternative treatment option according to current guidelines and it is already offered outside a registered study context. To draw a parallel, pCR rate after nCRT in rectal cancer is comparable (27%) to esophageal cancer (25–30%) [
1,
30,
31]. Also, the risk of local regrowth is comparable for both tumor types estimated to be 7–33% within 3 years in rectal cancer [
32‐
34] and around 30% in esophageal cancer (preliminary data from the SANO trial and SANO-2 study). The combined diagnostic tests used in the response evaluation of rectal cancer (MRI, endorectal ultrasonography and CT) have a negative predictive value (NPV) ranging from 42–53% [
35]. In esophageal cancer, detection of regrowth with upper endoscopy, EUS and FDG-PET/CT has a NPV ranging from 35–44% [
17]. Rectal cancer surgery is associated with a 31% rate of major complications, approximately 25% of patients have a permanent stoma and anorectal and sexual dysfunction is seen in more than 60% of patients [
36‐
38]. After esophagectomy, over 60% of patients get a complication with 25% classified as major and the 30-day mortality rate is around 3%. Esophagectomy has a great impact on patient’s quality of life lasting for years after surgery [
1]. The morbidity associated with surgery for both tumor types supports the exploration and implementation for less invasive treatments. Although watchful waiting is already being applied in patients with rectal cancer, active surveillance in patients with esophageal cancer is still under investigation and should be carefully evaluated before implementation on a wider scale.
The SANO-2 study offers a platform to assess the quality of active surveillance by registration of CREs, treatment-related complications and survival. Multidisciplinary meetings with participating centers are organized to discuss possible safety issues and learn from experience. Participating centers receive feedback on the completeness and quality of clinical response evaluations and outcomes including patient-reported quality of life.
Acknowledgements
We would like to thank all the nurse practitioners and research nurses of the SANO-consortium for their help and involvement in this study.
Collaborators of the SANO-2 study group
Jan Willem T. Dekker, MD, PhD,8 Willem E. Fiets, MD, PhD,9 Hendrik H. Hartgrink, MD, PhD,10 Wouter L. Hazen, MD, PhD,11 Ewout A. Kouwenhoven, MD, PhD,12 Grard A.P. Nieuwenhuijzen, MD, PhD,13 Camiel Rosman, MD, PhD,14 Johanna W. van Sandick, MD, PhD,15 Meindert N. Sosef, MD, PhD,16 Edwin S. van der Zaag, MD, PhD,17
8 Department of Surgery, Reinier de Graaf Group, Delft, the Netherlands.
9 Department Medical Oncology, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
10 Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
11 Department of Gastroenterology, Elisabeth Tweesteden Hospital, Tilburg, the Netherlands.
12 Department of Surgery, Zorggroep Twente, Almelo, the Netherlands.
13 Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
14 Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
15 Department of Surgery, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
16 Department of Surgery, Zuyderland Medical Center, Heerlen, the Netherlands.
17 Department of Surgery, Gelre Hospital, Apeldoorn, the Netherlands.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.